Kyoto University Graduate School of Medicine Reports Findings in Rectal Cancer (Relationship between diverting stoma and adjuvant chemotherapy in patients with rectal cancer: a nationwide study using the National Database of Health Insurance …): Oncology – Rectal Cancer

2021 NOV 26 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- New research on Oncology - Rectal Cancer is the subject of a report. According to news reporting originating from Kyoto, Japan, by NewsRx correspondents, research stated, “Patients at risk of recurrence after curative surgery for rectal cancer usually receive adjuvant chemotherapy. Postoperative recovery after low anterior resection (LAR) for rectal cancer can be improved by placement of a diverting stoma to reduce anastomotic leakage.”

Our news editors obtained a quote from the research from the Kyoto University Graduate School of Medicine, “However, it remains unclear how a diverting stoma affects administration of adjuvant chemotherapy in these patients. We identified Japanese patients with rectal cancer who underwent LAR in 2014 and received adjuvant chemotherapy within 12 months of surgery in the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Doses of five types of chemotherapy administered (tegafur/uracil, tegafur/gimeracil/oteracil potassium, capecitabine, 5-fluorouracil, and oxaliplatin) were assessed according to the presence or absence of diverting stoma and the timing of stoma closure. There was no significant difference in the cumulative doses of chemotherapy administered in the 12 months after LAR between patients with and without diverting stoma, but more doses were administered in the early postoperative period (0-2 months after LAR) in patients without diverting stoma. Also, more doses of chemotherapy, regardless of type, were administered in the late closure group (7-12 months after LAR) than in the early closure ( 6 months) and no closure groups. Presence of a diverting stoma did not influence the dose of adjuvant chemotherapy administered within 12 months after LAR but could have delayed the start of adjuvant chemotherapy.”

According to the news editors, the research concluded: “Patients with late closure of a diverting stoma received more doses of adjuvant chemotherapy administered over 12 months.”

This research has been peer-reviewed.

For more information on this research see: Relationship between diverting stoma and adjuvant chemotherapy in patients with rectal cancer: a nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan. International Journal of Clinical Oncology, 2021. International Journal of Clinical Oncology can be contacted at: Springer Japan Kk, Shiroyama Trust Tower 5F, 4-3-1 Toranomon, Minato-Ku, Tokyo, 105-6005, Japan. (Springer - www.springer.com; International Journal of Clinical Oncology - http://www.springerlink.com/content/1341-9625/)

The news editors report that additional information may be obtained by contacting Nobuaki Hoshino, Dept. of Surgery, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. Additional authors for this research include Koya Hida, Yudai Fukui, Yoshimitsu Takahashi, Takeo Nakayama and Kazutaka Obama.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s10147-021-02079-4. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the International Journal of Clinical Oncology is: Springer Japan Kk, Shiroyama Trust Tower 5F, 4-3-1 Toranomon, Minato-Ku, Tokyo, 105-6005, Japan.

(Our reports deliver fact-based news of research and discoveries from around the world.)